Bio-Rad Laboratories FY 2023: revenue $2.7B, down 5%; diluted EPS −$21.82

Key figures from this report

These are the numbers Bio-Rad Laboratories reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$2.7B−5% from $2.8B in FY 202210-K income statement, on EDGAR
2. Net income−$637.3MAgainst −$3.6B in FY 202210-K income statement, on EDGAR
3. Diluted EPS−$21.82Against −$121.79 in FY 202210-K income statement, on EDGAR
4. Cash and cash equivalents$403.8M−7% from $434.2M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$374.9M+93% from $194.4M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables